Tinidazole Shortage: What Providers and Prescribers Need to Know in 2026

Prescribers and clinical pharmacists managing patients who need tinidazole may encounter patient reports of difficulty filling their prescriptions. While tinidazole is not in an active FDA-designated shortage as of 2026, it remains a niche antiprotozoal/antibacterial that is not routinely stocked at all pharmacy locations. This guide equips providers with current availability information, evidence-based therapeutic alternatives by indication, and actionable strategies to support patients facing dispensing challenges.

Current FDA Shortage Status (2026)

Tinidazole is not listed in the FDA Drug Shortages Database or the ASHP Drug Shortage Resource Center as of 2026. Generic tinidazole is manufactured by several companies including Hikma Pharmaceuticals, Edenbridge Pharmaceuticals, and Novel Laboratories, providing multi-source supply that reduces the risk of a sustained national shortage.

However, because tinidazole is prescribed for a narrow set of conditions relative to other antibiotics, many retail and independent pharmacies maintain minimal inventory and may not have it on hand when a prescription is presented. Patients who encounter this situation are often frustrated by the lack of an immediate explanation.

Why Tinidazole Availability Gaps Occur

Even without an official shortage designation, real-world availability gaps are driven by:

Low dispensing volume: Tinidazole is prescribed far less frequently than metronidazole. Many pharmacies treat it as a low-priority stocking item.

Regional wholesale variability: Wholesalers may be temporarily backordered on specific manufacturers' generic formulations, causing local scarcity without triggering FDA shortage designations.

250 mg strength limited availability: The 250 mg tablet is much harder to source than the 500 mg tablet. If pediatric dosing or specific adult regimens require 250 mg tablets, expect more dispensing challenges.

Brand Tindamax cost: Brand Tindamax costs over $800 for a 60-tablet supply and is rarely stocked. Ensure prescriptions are written for generic tinidazole.

Evidence-Based Alternatives by Indication

Bacterial Vaginosis (BV)

CDC 2021 STI Treatment Guidelines list the following alternatives to tinidazole for BV:

Metronidazole 500 mg orally twice daily for 7 days (preferred first-line)

Metronidazole gel 0.75% (one applicator vaginally once daily x 5 days)

Secnidazole (Solosec) 2 g oral granule packet, single dose—approved for BV

Clindamycin 300 mg orally twice daily for 7 days (preferred alternative for nitroimidazole allergy)

Clindamycin vaginal cream 2% (one applicator intravaginally nightly x 7 days)

Trichomoniasis

Metronidazole 2 g orally as a single dose (preferred for non-pregnant patients)

Metronidazole 500 mg twice daily for 7 days (for women; may improve cure rates)

Secnidazole (Solosec) 2 g single-dose granule packet—FDA-approved for trichomoniasis (2021)

Note: Nitroimidazoles are the only class with demonstrated clinical efficacy against T. vaginalis. In nitroimidazole allergy, consult with infectious disease.

Giardiasis

Metronidazole 250 mg three times daily for 5-7 days (adults)

Nitazoxanide (Alinia) 500 mg twice daily x 3 days (adults); 100 mg BID x 3 days (ages 1-3); 200 mg BID x 3 days (ages 4-11)

Amebiasis (Intestinal and Hepatic)

Metronidazole 750 mg orally three times daily for 7-10 days (tissue amebicide), followed by an intraluminal agent

Intraluminal agents: paromomycin 500 mg three times daily x 7 days or iodoquinol 650 mg three times daily x 20 days

Prescribing Considerations When Substituting

Confirm absence of nitroimidazole allergy before substituting metronidazole for tinidazole—approximately 38% of T. vaginalis isolates resistant to metronidazole also show reduced susceptibility to tinidazole (cross-resistance).

Both tinidazole and metronidazole carry the same pregnancy Category B classification (first trimester contraindicated). Secnidazole and clindamycin have distinct pregnancy considerations—review labeling before prescribing.

Alcohol restriction applies to both metronidazole and tinidazole (avoid during treatment and for 3 days after). Ensure patient counseling is updated if switching regimens.

For trichomoniasis, treat partners simultaneously regardless of which nitroimidazole is prescribed.

Supporting Your Patients: medfinder for Providers

If your patients are having consistent difficulty locating tinidazole at their local pharmacy, recommend medfinder for providers. medfinder contacts pharmacies in the patient's area to identify which ones have the medication in stock, then texts results directly to the patient. This eliminates the burden of phone-based pharmacy searching for both your patients and your office staff.

Additional Resources for Providers

Our companion guide, How to Help Your Patients Find Tinidazole in Stock, provides step-by-step guidance on pharmacy navigation, prescription transfer workflows, and patient communication scripts.